Sokolova V I, Kuznetsova S M, Kamnev Iu V
Antibiot Khimioter. 1990 May;35(5):36-9.
Amikacin sensitivity of 157 strains which caused infectious inflammatory diseases in patients of a therapeutic hospital was studied. It was shown that 52 and 42.9% of the isolates from patients with bronchopulmonary infections were highly and moderately sensitive to amikacin, respectively. 5 pneumococcal strains were resistant to amikacin. Among the isolates from urine of the patients with urinary infections there were no strains resistant to amikacin. Study of amikacin pharmacokinetics demonstrated expediency of antibiotic endobronchial administration to patients with bronchopulmonary diseases and aggravation of chronic purulent inflammatory processes. A favourable clinical effect of amikacin after its intramuscular or endobronchial administration was observed in 53.3% of the patients. In 30% of the patients the effect was satisfactory. In 16.7% of the patients the treatment failed. Satisfactory antibiotic tolerance in the majority of the patients was stated.
对一家治疗医院中导致患者感染性炎症疾病的157株菌株进行了阿米卡星敏感性研究。结果表明，支气管肺部感染患者分离出的菌株中，分别有52株（占42.9%）对阿米卡星高度敏感和中度敏感。有5株肺炎球菌菌株对阿米卡星耐药。在泌尿系统感染患者尿液分离出的菌株中，没有对阿米卡星耐药的菌株。对阿米卡星药代动力学的研究表明，对支气管肺部疾病患者进行抗生素支气管内给药以及加重慢性化脓性炎症过程是适宜的。在53.3%的患者中观察到阿米卡星肌内注射或支气管内给药后有良好的临床效果。在30%的患者中效果令人满意。在16.7%的患者中治疗失败。大多数患者对抗生素耐受性良好。
